Intellia outlines 2026 lonvo-z launch plans as FDA lifts...

2026-02-26 21:48:26 ET More on Intellia Therapeutics Intellia Therapeutics, Inc. (NTLA) Q4 2025 Earnings Call Transcript Intellia Therapeutics: 2 Major Catalysts Will Determine Stock's Trajectory In 2026 Intellia Therapeutics: Maintaining A Sell Rating As Platform Risks Escalate Intellia Therapeutics GAAP EPS of -$0.83 beats by $0.12, revenue of $23.02M beats by $10.85M Rare disease pharmas could benefit from FDA guidance to accelerate development Read the full article on Seeking Alpha For further details see: Intellia outlines 2026 lonvo-z launch plans as FDA lifts clinical hold on MAGNITUDE-2